These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34970476)

  • 1. Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China.
    Yu YF; Luan L; Zhu FF; Dong P; Ma LH; Li LT; Gao L; Lu S
    Front Oncol; 2021; 11():564234. PubMed ID: 34970476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China.
    Xu X; Fang N; Li H; Liu Y; Yang F; Li X
    Ann Transl Med; 2021 May; 9(9):760. PubMed ID: 34268373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (
    Nilsson FOL; Gal P; Houisse I; Ivanova JI; Asanin ST
    J Med Econ; 2021; 24(1):447-457. PubMed ID: 33754924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.
    Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Trigo-Vicente C; Cortijo J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):637-646. PubMed ID: 34602008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis.
    Aguilar-Serra J; Gimeno-Ballester V; Pastor-Clerigues A; Milara J; Marti-Bonmati E; Trigo-Vicente C; Cortijo J
    J Comp Eff Res; 2021 Mar; 10(4):325-335. PubMed ID: 33635095
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer.
    Zhang L; Li N; Liu M; Zheng B; Wu Z; Cai H
    Cancer Manag Res; 2021; 13():4263-4270. PubMed ID: 34093040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
    BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China.
    Shu Y; Zhang Q; He X; Chen L
    Cancer Manag Res; 2021; 13():8297-8306. PubMed ID: 34764692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib versus platinum-pemetrexed in patients with previously treated EGFR T790M advanced non-small cell lung cancer: An updated AURA3 trial-based cost-effectiveness analysis.
    Shi Y; Pei R; Liu S
    Front Oncol; 2022; 12():833773. PubMed ID: 36324594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.
    Zeng X; Li J; Peng L; Wang Y; Tan C; Chen G; Wan X; Lu Q; Yi L
    PLoS One; 2014; 9(2):e88881. PubMed ID: 24586426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.
    You JHS; Cho WCS; Ming WK; Li YC; Kwan CK; Au KH; Au JS
    PLoS One; 2021; 16(3):e0247860. PubMed ID: 33647045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
    Zhu J; Li T; Wang X; Ye M; Cai J; Xu Y; Wu B
    BMC Cancer; 2013 Jan; 13():39. PubMed ID: 23360224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
    Shu Y; Ding Y; He X; Liu Y; Wu P; Zhang Q
    Front Pharmacol; 2022; 13():920479. PubMed ID: 36204237
    [No Abstract]   [Full Text] [Related]  

  • 15. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
    Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models.
    Gao L; Li SC
    Appl Health Econ Health Policy; 2019 Jun; 17(3):371-380. PubMed ID: 30535675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
    Cheng Y; Mok TS; Zhou X; Lu S; Zhou Q; Zhou J; Du Y; Yu P; Liu X; Hu C; Lu Y; Zhang Y; Lee KH; Nakagawa K; Linke R; Wong CH; Tang Y; Zhu F; Wilner KD; Wu YL
    Lung Cancer; 2021 Apr; 154():176-185. PubMed ID: 33721611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations.
    Li J; Nickens D; Wilner K; Tan W
    Oncol Ther; 2021 Dec; 9(2):525-539. PubMed ID: 34120312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Lee M; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Wu YL
    J Clin Oncol; 2018 Aug; 36(22):2244-2250. PubMed ID: 29864379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.